Westlake Chemical's Q1 Earnings Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 11:00AM CDT
Westlake's (WLK) first-quarter 2014 revenues and earnings beat Zacks Consensus Estimates.
Westlake Chemical (WLK) Jumps: Stock Up 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:51AM CDT
Westlake Chemical Corp. (WLK) was a big mover last session, as its shares rose over 6% on the day.
Westlake Fly High on Ethylene Unit IPO Plans - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 6:00PM CDT
Shares of Westlake Chemical (WLK) shoot up after it announced its IPO plans for a newly formed ethylene unit.
Strategy To YieldBoost SHLM From 2.2% To 8.1% Using Options
at The Street - Fri Apr 25, 10:47AM CDT
Shareholders of A. Schulman, Inc.
Why You Shouldn't Bet Against A. Schulman (SHLM) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:00AM CDT
A. Schulman is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
A. Schulman Announces Long-Term Growth Targets At Investor Day
PR Newswire - Tue Apr 15, 4:26PM CDT
A. Schulman, Inc. (Nasdaq-GS: SHLM) today highlighted several new financial targets for the fiscal 2014-2018 period, as disclosed in presentations made by management at its 2014 Investor Day in New York on April 10, 2014 and filed with Schulman's Form 8-K dated April 10, 2014.
Is A. Schulman (SHLM) Stock a Great Combo of Value and Growth? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:50AM CDT
A. Schulman may be an interesting play thanks to its forward PE below 20, a P/S ratio below one, and a strong Zacks Rank
Company News for April 09, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 9:06AM CDT
Companies in the News are: GIMO,TISI,SHLM,ISCA
A. Schulman Authorizes $55 Million Stock Buyback Program
PR Newswire - Tue Apr 08, 7:30AM CDT
A. Schulman, Inc. (Nasdaq-GS: SHLM) announced today that its Board of Directors approved a new share repurchase program ("Program"
A. Schulman Reports Strong Fiscal 2014 Second Quarter
PR Newswire - Mon Apr 07, 3:30PM CDT
-- Net income from continuing operations for the second quarter of fiscal 2014 was $6.5 million, or $0.22 per diluted share; adjusted net income from continuing operations for the second quarter of fiscal 2014, excluding certain items, was $11.3 million, or $0.39 per diluted share, a 39% improvement over the prior-year quarter
A. Schulman To Review Strategic Progress and Future Growth Plans at 2014 Investor Day
PR Newswire - Fri Apr 04, 2:34PM CDT
A. Schulman, Inc. (Nasdaq-GS: SHLM) will host an Investor Day on Thursday, April 10, in New York City to review the Company's current progress with its recent acquisitions and organic growth initiatives, as well as its future plans.
A. Schulman to Webcast Fiscal 2014 Second-Quarter Earnings Conference Call
GlobeNewswire - Mon Mar 24, 12:18PM CDT
A. Schulman Inc. (Nasdaq:SHLM) expects to release fiscal 2014 second-quarter results after the market closes on Monday, April 7, 2014. The Company will hold its fiscal 2014 second-quarter earnings conference call on Tuesday, April 8, at 10 a.m. Eastern time, with Joseph Gingo, Chairman, President and Chief Executive Officer, Bernard Rzepka, Executive Vice President and Chief Operating Officer, and Joseph Levanduski, Vice President and Chief Financial Officer.
Gabelli & Company 5th Annual Specialty Chemicals Conference
Business Wire - Tue Mar 04, 7:00AM CST
Gabelli & Company will host its Specialty Chemicals Conference on March 20, 2014 in New York City. This research meeting will feature presentations and one-on-one meetings with senior management of several leading specialty chemicals companies. Institutional investors should contact their salesperson for more information or to register.
Research and Markets: B-Cell Leukemia Global Clinical Trials Review, H1, 2014
Business Wire - Tue Mar 04, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/bgqrml/bcell_leukemia) has announced the addition of the "B-Cell Leukemia Global Clinical Trials Review, H1, 2014" report to their offering.
Westlake Hikes Dividend, Splits Stock - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 4:30PM CST
Westlake has raised dividend by 12% and declared a two-for-one stock split.
Shares of SHLM Up 16.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 03, 9:58AM CST
SmarTrend identified an Uptrend for Schulman (NASDAQ:SHLM) on September 20th, 2013 at $28.87. In approximately 5 months, Schulman has returned 16.83% as of today's recent price of $33.73.
Schulman Up 17.9% Since SmarTrend Uptrend Call (SHLM)
Comtex SmarTrend(R) - Mon Jan 27, 9:32AM CST
SmarTrend identified an Uptrend for Schulman (NASDAQ:SHLM) on September 20th, 2013 at $28.87. In approximately 4 months, Schulman has returned 17.91% as of today's recent price of $34.04.
A. Schulman (SHLM): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 7:54AM CST
A. Schulman might be an intriguing choice for investors as it is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
This Week's Growth & Income Stocks: (SHLM) (PEB) - Video Blog
Todd Bunton - Zacks Investment Research - Wed Jan 22, 3:20PM CST
Growth & Income Stock Strategist, Todd Bunton, highlights A. Schulman (SHLM) and Pebblebrook Hotel Trust (PEB) on January 22, 2014.
Uptrend Call Working As Schulman Stock Rises 19.5% (SHLM)
Comtex SmarTrend(R) - Fri Jan 17, 5:09PM CST
SmarTrend identified an Uptrend for Schulman (NASDAQ:SHLM) on September 20th, 2013 at $28.87. In approximately 4 months, Schulman has returned 19.54% as of today's recent price of $34.51.